Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Nina L. Jebsen"'
Publikováno v:
Anticancer Research. 43:2031-2039
Autor:
Tatiana Georgiesh, Ninna Aggerholm-Pedersen, Patrick Schöffski, Yifan Zhang, Andrea Napolitano, Judith V. M. G. Bovée, Åse Hjelle, Gordon Tang, Mateusz Spalek, Margherita Nannini, David Swanson, Thomas Baad-Hansen, Raf Sciot, Asle C. Hesla, Paul Huang, Desiree Dorleijn, Hans Kristian Haugland, Maribel Lacambra, Jacek Skoczylas, Maria A. Pantaleo, Rick L. Haas, Leonardo A. Meza-Zepeda, Florian Haller, Anna M. Czarnecka, Herbert Loong, Nina L. Jebsen, Michiel van de Sande, Robin L. Jones, Felix Haglund, Iris Timmermans, Akmal Safwat, Bodil Bjerkehagen, Kjetil Boye
Publikováno v:
British Journal of Cancer, 127(10), 1793-1798. SPRINGERNATURE
Georgiesh, T, Aggerholm-Pedersen, N, Schoffski, P, Zhang, Y, Napolitano, A, Bovee, J V M G, Hjelle, A, Tang, G, Spalek, M, Nannini, M, Swanson, D, Baad-Hansen, T, Sciot, R, Hesla, A C, Huang, P, Dorleijn, D, Haugland, H K, Lacambra, M, Skoczylas, J, Pantaleo, M A, Haas, R L, Meza-Zepeda, L A, Haller, F, Czarnecka, A M, Loong, H, Jebsen, N L, van de Sande, M, Jones, R L, Haglund, F, Timmermans, I, Safwat, A, Bjerkehagen, B & Boye, K 2022, ' Validation of a novel risk score to predict early and late recurrence in solitary fibrous tumour ', British Journal of Cancer, vol. 127, pp. 1793–1798 . https://doi.org/10.1038/s41416-022-01959-4
Georgiesh, T, Aggerholm-Pedersen, N, Schoffski, P, Zhang, Y, Napolitano, A, Bovee, J V M G, Hjelle, A, Tang, G, Spalek, M, Nannini, M, Swanson, D, Baad-Hansen, T, Sciot, R, Hesla, A C, Huang, P, Dorleijn, D, Haugland, H K, Lacambra, M, Skoczylas, J, Pantaleo, M A, Haas, R L, Meza-Zepeda, L A, Haller, F, Czarnecka, A M, Loong, H, Jebsen, N L, van de Sande, M, Jones, R L, Haglund, F, Timmermans, I, Safwat, A, Bjerkehagen, B & Boye, K 2022, ' Validation of a novel risk score to predict early and late recurrence in solitary fibrous tumour ', British Journal of Cancer, vol. 127, pp. 1793–1798 . https://doi.org/10.1038/s41416-022-01959-4
Background: Current risk models in solitary fibrous tumour (SFT) were developed using cohorts with short follow-up and cannot reliably identify low-risk patients. We recently developed a novel risk model (G-score) to account for both early and late r
Autor:
Nina L. Jebsen, Brynjar Mauseth, Ketil André Camilio, Ahmad Awada, George Lazaridis, Christiane Jungels, Hamina Patel, Aurélien Marabelle, Vibeke Sundvold, Fabienne Hermitte, Delphine Loirat, James Spicer, Øystein Rekdal, Berit Nicolaisen, R Kristeleit, Paal Brunsvig, Andrew Saunders, Dag Erik Jøssang, Jérôme Galon, Baldur Sveinbjørnsson, Jean Francois Baurain
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. xx, no.xx, p. xx (2021)
Purpose: LTX-315 is a first-in-class, 9-mer membranolytic peptide that has shown potent immunomodulatory properties in preclinical models. We conducted a phase I dose-escalating study of intratumoral LTX-315 administration in patients with advanced s
Autor:
A.N. Scholten, Augustinus D.G. Krol, Aisha Miah, Nina L. Jebsen, Elizabeth H. Baldini, Uta Flucke, Khin Thway, Houke M. Klomp, Piet van den Ende, Winan J. van Houdt, Hester van Boven, Erik van Werkhoven, Yvonne Schrage, Judith V.M.G. Bovée, Jos A. van der Hage, Jan F. Ubbels, Rick L. Haas, Pètra M. Braam, Johannes J. Bonenkamp, Shane Zaidi, Øyvind S. Bruland, Jules Lansu, Winette T. A. van der Graaf, Frits van Coevorden
Publikováno v:
JAMA Oncology, 7(1):205865. American Medical Association
JAMA Oncology, 7(1). American Medical Association
JAMA Oncology, 7(1). AMER MEDICAL ASSOC
Jama Oncology, 7
JAMA Oncol
JAMA oncology, 7(1), 1-8. AMER MEDICAL ASSOC
Jama Oncology, 7, 1
JAMA Oncology, 7(1). American Medical Association
JAMA Oncology, 7(1). AMER MEDICAL ASSOC
Jama Oncology, 7
JAMA Oncol
JAMA oncology, 7(1), 1-8. AMER MEDICAL ASSOC
Jama Oncology, 7, 1
Item does not contain fulltext IMPORTANCE: Currently, preoperative radiotherapy for all soft-tissue sarcomas is identical at a 50-Gy dose level, which can be associated with morbidity, particularly wound complications. The observed clinical radiosens
Autor:
Oskar Hagberg, Karin Papworth, Kirsten Sundby Hall, Bodil Bjerkehagen, Elisabet Lidbrink, Nina L. Jebsen, Hans Hagberg, Clement S. Trovik, Mikael Eriksson, Øyvind S. Bruland, Henrik C. F. Bauer
Publikováno v:
Clinical Sarcoma Research, Vol 10, Iss 1, Pp 1-9 (2020)
Clinical Sarcoma Research
Clinical Sarcoma Research
Background We recently reported outcomes from a Scandinavian Sarcoma Group adjuvant study (SSG XX group A) conducted on localized and operable high risk soft tissue sarcoma (STS) of the extremities and trunk wall. SSG XX, group B, comprised of patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd2ded381e33b3c7f0329543d71829b7
http://hdl.handle.net/10852/81138
http://hdl.handle.net/10852/81138
Autor:
Emelie Styring, Erkki Tukiainen, Olga Zaikova, Najme Wall, Kirsten Sundby Hall, Tuula Lehtinen, Anders Kalén, Nina L. Jebsen, Thor Alvegård, Mikael Skorpil, Mika Sampo, Bodil Bjerkehagen, Clement S. Trovik, Sigvard Eriksson, Geir Egil Eide, Ingela Johansson, Minna Laitinen, Mikael Eriksson, Halldór Jónsson, Helgi Sigurðsson, Elisabeth Johansson, Henrik C. F. Bauer, Fredrik Vult von Steyern
Publikováno v:
Acta Orthopaedica
Acta Orthopaedica, Vol 88, Iss 3, Pp 341-347 (2017)
Acta Orthopaedica, Vol 88, Iss 3, Pp 341-347 (2017)
Purpose - We wanted to examine the potential of the Scandinavian Sarcoma Group (SSG) Central Register, and evaluate referral and treatment practice for soft-tissue sarcomas in the extremities and trunk wall (STS) in the Nordic countries. Background -
Autor:
Nina L. Jebsen, Torunn Oveland Apelseth, Bjørn Tore Gjertsen, Hamina Patel, Dag Eirik Jøssang, Hans Kristian Haugland, Øystein Rekdal
Publikováno v:
Journal of Medical Case Reports
Journal of Medical Case Reports, Vol 13, Iss 1, Pp 1-9 (2019)
Journal of Medical Case Reports, Vol 13, Iss 1, Pp 1-9 (2019)
Source at https://doi.org/10.1186/s13256-019-2088-6. Background - Desmoid tumors are intermediary malignant, fibrous lesions occurring in various soft tissues. Surgical treatment is relentlessly challenging because of the propensity for local aggress
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da057b2d9a5c4dcb3a30a5c3b43e4607
https://hdl.handle.net/10037/16430
https://hdl.handle.net/10037/16430
Autor:
Nina L. Jebsen, Øyvind S. Bruland, Sigvard Eriksson, Panagiotis Tsagozis, Asle C. Hesla, Emelie Styring
Publikováno v:
Journal of Bone Oncology
Journal of Bone Oncology, Vol 14, Iss, Pp-(2019)
Journal of Bone Oncology, Vol 14, Iss, Pp-(2019)
Object: Many patients with Ewing sarcoma (ES) of the mobile spine present with neurologic symptoms leading to emergency decompressive surgery. Only rarely is optimal treatment involving neo-adjuvant chemotherapy followed by en bloc excision possible.
Autor:
Nina L. Jebsen, Henrik C. F. Bauer, Olga Zaikova, Panagiotis Tsagozis, Asle C. Hesla, Otte Brosjö
Publikováno v:
Journal of Bone and Joint Surgery. 98:199-210
Background Treatment of Ewing sarcoma of the pelvic bones remains one of the most difficult tasks in the treatment of bone sarcomas. Whether surgery or radiation therapy is the best local treatment is still a matter of debate. The aim of the present
Autor:
Virginia Ferraresi, Stefan S. Bielack, Anna Paioli, Nina L. Jebsen, Kirsten Sundby Hall, Peter Reichardt, Fatime Krasniqi, Bodil Bjerkehagen, Alessandra Longhi, Otte Brosjö, Thekla von Kalle, Emanuela Palmerini, Marco Gambarotti, Stefano Ferrari, Matthias Kevric, Rossella Bertulli, Per Ulf Tunn, Benjamin Sorg, Wolfgang E. Berdel, Piero Picci, Davide Maria Donati, Mikael Eriksson, Mathias Werner, Rudolf Schwarz, Odd R. Monge, Sylvie Lorenzen, Anne Katrin Kasparek, Marilena Cesari, Sigbjørn Smeland, Alessandro Comandone, Giovanni Grignani, Stefanie Hecker-Nolting, Gerlinde Egerer
Publikováno v:
Tumori. 104(1)
Introduction: The EUROpean Bone Over 40 Sarcoma Study (EURO-B.O.S.S.) was the first prospective international study for patients 41-65 years old with high-grade bone sarcoma treated with an intensive chemotherapy regimen derived from protocols for yo